Related Issuers
by Stephen Carter
Mar 25, 2024 6:38 AM ET
Neopharmed Gentili SpA EUR750m144A/Reg S fixed/floating sr sec notes 2-part. (Expect B3)/B/B+ (--/sable/stable). Via BNP (B&D)/GS jt physical books/IMI jt glocos/Banca Akros/CA/JPM/Natixis jt books. No reg rights. List Lux. NY law. Settles 04/08.
- EUR TBD (EUR300m minimum) sr sec FRN due 2030 (6y). NC1 (MWC B+50bp), then at 101, par.
- EUR TBD (EUR300m minimum) sr sec fixed-rate notes due 2030 (6y). NC2 (MWC B+50bp) (50%,25%,par). Equity claw: 2y 40%. Special call: 10% per year the first 2 years at 103.
Investor call at 11am UKT today, Q&A sessions today-Weds. UOP: repay the existing EUR700m unitranche notes, and EUR26m for cash on the B/S. Equity sponsors: Ardian and NB Renaissance. Biz: a leading primary care pharmaceutical company in Italy that promotes a well-established and diversified portfolio of leading branded off-patent products. HQ: Milan, Italy.